Peripheral T-cell lymphoma market to grow 7% CAGR by 2036 with new therapies boosting treatment options.

The peripheral T-cell lymphoma (PTCL) treatment market is expected to expand at a compound annual growth rate (CAGR) of 7% from 2026 to 2036, driven by rising incidence and new drug launches. Key emerging therapies like Duvelisib, Lacutamab, Linperlisib, KEYTRUDA, and OPDIVO are anticipated to transform treatment approaches and improve patient outcomes. The U.S. leads the market with 68% share and about 12,000 new cases in 2025. Advances in targeted therapies and biomarker-driven treatments promise a significant shift in PTCL management over the next decade.